drugset / Trial / NCT04384393
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
NaSequentialOpen-labelTreatment
Summary
This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.
Timeline
- Start
- 2020-05-09
- Primary completion
- 2022-11-10
- Completion
- 2023-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19 | Cell therapy | 200000 cells/kg | — |
| Subject | ThisCART19 | Cell therapy | 6e+07 cells/kg | — |